GLPwatch
Byetta for Depression
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for depression. Research in animal models suggests potential antidepressant-like effects, but human studies are limited and mixed, with one study noting increased depressive scores linked to stress.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Depression |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Byetta is not FDA-approved for depression; the research below reflects investigational or off-label study only.
Research on exenatide for depression (7)
- The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.
- p38<i>β</i> Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial <i>β</i>-Endorphin Expression.
- Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.
- Exenatide, a GLP-1 analog, has healing effects on LPS-induced autism model: Inflammation, oxidative stress, gliosis, cerebral GABA, and serotonin interactions.
- Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus: Exenatide Use Mediates Depressive Scores Through Increased Perceived Stress Levels.
- The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity.
- Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model.